C4X Discovery - Preliminary Results For The Year Ended 31 July 2015
28 October, 2015 – C4X Discovery Holdings plc (“C4XD”), a leader in rational drug discovery and design, is pleased to announce its preliminary results for the year ended 31 July 2015.
Corporate Highlights
• Successful IPO on AIM completed in October 2014 raising £11.0 million before expenses
• Orexin programme candidate drug progressed into formal pre-clinical and safety studies
• Renewal of our collaboration with Evotec AG (“Evotec”) providing access to C4XD’s conformational design technology
• Renewal of our collaboration with Takeda Cambridge Ltd (“Takeda”) providing access to C4XD’s conformational design technology
• Entered into research agreement with Evotec to develop back up series for C4XD’s Orexin programme
• Expansion of senior team to provide biology, pre-clinical and early stage clinical expertise
Financial highlights
• Cash, cash equivalents and deposits at 31 July 2015 of £7.5 million (31 July 2014: £0.7 million) • Total assets at 31 July 2015 of £8.7 million (31 July 2014: £1.2 million)
Progress since year end
• Collaboration with the University of Oxford’s Structural Genomics Consortium department (“SGC-Oxford”), providing access to protein structural information, expressed protein and assays
• Identified novel lead molecules that activate GPR142, a key factor in the production of insulin
• Designed novel activators for the NRF-2 pathway, important in mediating diseases such as Chronic Obstructive Pulmonary Disease (“COPD”) and Multiple Sclerosis (“MS”)
Chairman’s statement
“With the successful IPO, C4XD has secured the funding that enables us to advance our lead programme in Orexin, for the treatment of addiction, into formal pre-clinical safety and toxicity studies,” stated Clive Dix, Chairman of C4XD. “We have also designed lead compounds against multiple targets, further validating our platform. The support and confidence of our collaboration partners, AstraZeneca, Evotec and Takeda, now joined by the Structural Genomics Consortium provides independent recognition of the significant impact our novel approach can make in enabling ultra rational drug design. I am delighted with the progress made since IPO and believe the business is well positioned to deliver future value for shareholders.”
For further information please contact:
C4X Discovery Holdings plc
Piers Morgan, CEO
07912 293832
Zeus Capital
Dan Bate / Jonathan Sharp
0161 831 1512
Dominic Wilson
020 3829 5000
FTI Consulting
Matthew Cole / Brett Pollard / Rob Winder / Matthew Moss
020 3727 1000
C4XD began trading on the AIM market of the London Stock Exchange in October 2014 under the ticker symbol C4XD. For further information please visit: www.c4xdiscovery.com.
Help employers find you! Check out all the jobs and post your resume.
Corporate Highlights
• Successful IPO on AIM completed in October 2014 raising £11.0 million before expenses
• Orexin programme candidate drug progressed into formal pre-clinical and safety studies
• Renewal of our collaboration with Evotec AG (“Evotec”) providing access to C4XD’s conformational design technology
• Renewal of our collaboration with Takeda Cambridge Ltd (“Takeda”) providing access to C4XD’s conformational design technology
• Entered into research agreement with Evotec to develop back up series for C4XD’s Orexin programme
• Expansion of senior team to provide biology, pre-clinical and early stage clinical expertise
Financial highlights
• Cash, cash equivalents and deposits at 31 July 2015 of £7.5 million (31 July 2014: £0.7 million) • Total assets at 31 July 2015 of £8.7 million (31 July 2014: £1.2 million)
Progress since year end
• Collaboration with the University of Oxford’s Structural Genomics Consortium department (“SGC-Oxford”), providing access to protein structural information, expressed protein and assays
• Identified novel lead molecules that activate GPR142, a key factor in the production of insulin
• Designed novel activators for the NRF-2 pathway, important in mediating diseases such as Chronic Obstructive Pulmonary Disease (“COPD”) and Multiple Sclerosis (“MS”)
Chairman’s statement
“With the successful IPO, C4XD has secured the funding that enables us to advance our lead programme in Orexin, for the treatment of addiction, into formal pre-clinical safety and toxicity studies,” stated Clive Dix, Chairman of C4XD. “We have also designed lead compounds against multiple targets, further validating our platform. The support and confidence of our collaboration partners, AstraZeneca, Evotec and Takeda, now joined by the Structural Genomics Consortium provides independent recognition of the significant impact our novel approach can make in enabling ultra rational drug design. I am delighted with the progress made since IPO and believe the business is well positioned to deliver future value for shareholders.”
For further information please contact:
C4X Discovery Holdings plc
Piers Morgan, CEO
07912 293832
Zeus Capital
Dan Bate / Jonathan Sharp
0161 831 1512
Dominic Wilson
020 3829 5000
FTI Consulting
Matthew Cole / Brett Pollard / Rob Winder / Matthew Moss
020 3727 1000
C4XD began trading on the AIM market of the London Stock Exchange in October 2014 under the ticker symbol C4XD. For further information please visit: www.c4xdiscovery.com.
Help employers find you! Check out all the jobs and post your resume.